HomeCompareERFB vs ABBV

ERFB vs ABBV: Dividend Comparison 2026

ERFB yields 20000000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERFB wins by $4.875981653489057e+49M in total portfolio value
10 years
ERFB
ERFB
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full ERFB calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — ERFB vs ABBV

📍 ERFB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERFBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERFB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERFB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERFB
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ERFB beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERFB + ABBV for your $10,000?

ERFB: 50%ABBV: 50%
100% ABBV50/50100% ERFB
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ERFB
No analyst data
Altman Z
-1247.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERFB buys
0
ABBV buys
0
No recent congressional trades found for ERFB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERFBABBV
Forward yield20000000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.875981653489057e+49M$104.7K
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$25,725.73
Total dividends collected$4.875978515990276e+49M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ERFB vs ABBV ($10,000, DRIP)

YearERFB PortfolioERFB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,559$438.51+$2000.00MERFB
2$373,835,915,712,384$373,833,775,700,934.50$13,494$640.86+$373835915.70MERFB
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$15,951$945.97+$65304953364964.95MERFB
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$19,152$1,413.89+$10661728832755499008.00MERFB
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$23,443$2,146.38+$1.626767783781495e+24MERFB
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$29,391$3,321.96+$2.319743300546251e+29MERFB
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$37,948$5,265.87+$3.0915106403922057e+34MERFB
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$50,795$8,596.74+$3.8505079858392777e+39MERFB
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$71,034$14,549.41+$4.4821026103531426e+44MERFB
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$104,715$25,725.73+$4.875981653489057e+49MERFB

ERFB vs ABBV: Complete Analysis 2026

ERFBStock

ERF Wireless, Inc. provides wireless broadband access solutions for the energy industry in North America. The company conducts its operations through Energy Broadband, Inc., Wireless Bundled Services Division, and Enterprise Network Services segments. It offers wireless bandwidth and related support services, including nomadic terrestrial wireless broadband circuit connectivity to the wellsite; wellsite communications equipment rental; wellsite IT support services; wellsite IT services over broadband; network monitoring and maintenance:; layer 2 secure communications connectivity products rental and services; fixed site terrestrial wireless broadband connectivity; network design and construction; production field supervisory control and data acquisition; and midstream communications, monitoring, and security solutions for the oil and gas industry. The company also provides enterprise-level wireless bandwidth product and services, such as design and implementation of custom Internet wireless bandwidth solutions, including long-term maintenance and network monitoring; reselling arrangements; and secure connectivity services through its CryptoVue product to the regional banking, healthcare, and educational sectors primarily in the rural areas of North America. In addition, it offers commercial and residential wireless bandwidth products and services comprising -speed Internet, voice over Internet protocol services, network monitoring and maintenance services, and video services to commercial businesses and residential customers. The company was founded in 1986 and is headquartered in League City, Texas.

Full ERFB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ERFB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERFB vs SCHDERFB vs JEPIERFB vs OERFB vs KOERFB vs MAINERFB vs JNJERFB vs MRKERFB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.